News

  • Fassisi GmbH & Future Diagnostics

    A two day training session was made possible for the Lower Saxony company Fassisi GmbH. Fassisi is a German manufacturer of lateral-flow on-site rapid assays for livestock and companion animals. The Regional Access Brokers of IN2LS found a company from the Netherlands that is able to support the head of R&D and a technician from Fassisi in getting more insight in regard to the development of immunoassays and especially about competitive lateral flow immunoassays. Further collaboration between the two companies are likely to happen.

  • CINOGY can take first steps into Danish market with help of IN2LS

    CINOGY GmbH was established as a spin-off from the Laboratory for Laser and Plasma Technology of the University of Applied Sciences and Arts in Göttingen in 2006. CINOGY GmbH specializes in the development and production of innovative plasma processes and products in the fields of medicine and cosmetics. IN2LifeSciences was able to bring the company together with a Danish expert who will be able to deliver recommendations for a future approach in the Danish market. In this respect, IN2LifeSciences could lower the risk for the company to take its first steps into the Danish market.

  • InnatOss Laboratories gets valuable insight from Numerus

    The Dutch company InnatOss is conducting research for new alternative blood tests for ‘neglected diseases’ Lyme and Q fever. Especially research on Q fever plays an important role at the moment in the province of Brabant. For specific research to get insight into the scope of Q-fever in Brabant, InnatOss has applied for an IN2Lifesciences incentive.

    With the voucher and the help of BOM, InnatOss got in contact with the German company Numerus, a company specialized in statistical analysis of clinical trials. Numerus has given InnatOss valuable advice and expertise in how to gather and analyze data. It enabled them to take a step forward in their testing method of Q-fever. 

    Anja Garritsen, CEO of InnatOss: “BOM matched us with the German Numerus, a data-analyst usually working for big pharmaceutical companies. When we as a small company contacted them, we were taken seriously and received valuable advise concerning our data analysis.” She also hopes to have an entrance for the German market: “It might be a benefit for us that a well-known German company has been involved in our testing method.”

Pages